Changing the Fate of Dystrophin-Deficient Myoblasts via Hetero Ligand Nanoclusters on Biomaterial Surface: Effects of Integrin-Syndecan or Dystroglycan Crosstalk

preprint OA: closed
Full text JSON View at publisher

Abstract

Engineering skeletal muscle tissue regeneration, particularly in dystrophin-deficient muscles is dependent on facilitating myogenesis and recovery of myotube structure and function, which can be challenging due to compromised cell-extracellular matrix (ECM) interactions. The current study explored the potential impact of enhancing dystrophin-associated protein complex and focal adhesion formation and the interaction with associated target receptors to improve cellular response in both normal and Duchenne muscular dystrophy ( Dmd ) mutant myoblasts. This was achieved by multivalent dual ligands functionalization of RAFT-synthesized copolymer with fibronectin- and laminin-derived adhesion peptides (RGD, AG73, and A2G80) and their clustering at the biointerface. Our findings demonstrated the synergistic effect of integrin-syndecan/dystroglycan engagement and their clustering on enhancing myoblast adhesion, proliferation, and differentiation, partially overcoming the deficits caused by loss of dystrophin. Furthermore, enhanced focal adhesion formation and elevated receptor localization, particularly dystroglycan, at the sarcolemma were associated with improved structural organization, mechanical stability, and neuromuscular connectivity of myotubes. These results suggest a novel insight into harnessing next-generation molecularly engineered biomaterials with robust interaction with cells’ mechanosensors for advancing skeletal muscle tissue engineering, offering potential applications in the regeneration of dystrophic muscle and the development of neuromuscular disease models for drug testing. Abstract Figure Graphical Abstract/ToC Current work developed molecularly engineered biomaterial surfaces with nanoscale clustering of integrin-, syndecan-, and/or dystroglycan-binding peptides for skeletal muscle tissue regeneration. By controlling peptide distribution and type at the biointerface, cell adhesion, proliferation, and differentiation were modulated in dystrophin-deficient myoblasts. Accordingly, the results demonstrated significant improvement in myotube structural organization, mechanical stiffness, and their innervation in response to heteronanoclusters.
Full text 1,771 characters · extracted from oa-doi-fallback · click to expand
Abstract Engineering skeletal muscle tissue regeneration, particularly in dystrophin-deficient muscles is dependent on facilitating myogenesis and recovery of myotube structure and function, which can be challenging due to compromised cell-extracellular matrix (ECM) interactions. The current study explored the potential impact of enhancing dystrophin-associated protein complex and focal adhesion formation and the interaction with associated target receptors to improve cellular response in both normal and Duchenne muscular dystrophy (Dmd) mutant myoblasts. This was achieved by multivalent dual ligands functionalization of RAFT-synthesized copolymer with fibronectin- and laminin-derived adhesion peptides (RGD, AG73, and A2G80) and their clustering at the biointerface. Our findings demonstrated the synergistic effect of integrin-syndecan/dystroglycan engagement and their clustering on enhancing myoblast adhesion, proliferation, and differentiation, partially overcoming the deficits caused by loss of dystrophin. Furthermore, enhanced focal adhesion formation and elevated receptor localization, particularly dystroglycan, at the sarcolemma were associated with improved structural organization, mechanical stability, and neuromuscular connectivity of myotubes. These results suggest a novel insight into harnessing next-generation molecularly engineered biomaterials with robust interaction with cells’ mechanosensors for advancing skeletal muscle tissue engineering, offering potential applications in the regeneration of dystrophic muscle and the development of neuromuscular disease models for drug testing. Competing Interest Statement The authors have declared no competing interest. Data Availability Data will be made available on request from authors.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00